These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9706063)

  • 21. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.
    Zvada SP; Van Der Walt JS; Smith PJ; Fourie PB; Roscigno G; Mitchison D; Simonsson US; McIlleron HM
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3390-4. PubMed ID: 20516273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs.
    Dutta NK; Alsultan A; Peloquin CA; Karakousis PC
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1535-7. PubMed ID: 23295923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-performance liquid chromatography assay of rifapentine in human serum.
    He X; Wang J; Liu X; Chen X
    J Chromatogr B Biomed Appl; 1996 Jun; 681(2):412-5. PubMed ID: 8811456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.
    Langdon G; Wilkins J; McFadyen L; McIlleron H; Smith P; Simonsson US
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4429-36. PubMed ID: 16251279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rifapentine: its role in the treatment of tuberculosis.
    Temple ME; Nahata MC
    Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rifapentine.
    Jarvis B; Lamb HM
    Drugs; 1998 Oct; 56(4):607-16; discussion 617. PubMed ID: 9806107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
    Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.
    Rifat D; Prideaux B; Savic RM; Urbanowski ME; Parsons TL; Luna B; Marzinke MA; Ordonez AA; DeMarco VP; Jain SK; Dartois V; Bishai WR; Dooley KE
    Sci Transl Med; 2018 Apr; 10(435):. PubMed ID: 29618565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.
    Francis J; Zvada SP; Denti P; Hatherill M; Charalambous S; Mungofa S; Dawson R; Dorman S; Gupte N; Wiesner L; Jindani A; Harrison TS; Olagunju A; Egan D; Owen A; McIlleron HM
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
    Weiner M; Burman W; Vernon A; Benator D; Peloquin CA; Khan A; Weis S; King B; Shah N; Hodge T;
    Am J Respir Crit Care Med; 2003 May; 167(10):1341-7. PubMed ID: 12531776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
    Bock NN; Sterling TR; Hamilton CD; Pachucki C; Wang YC; Conwell DS; Mosher A; Samuels M; Vernon A;
    Am J Respir Crit Care Med; 2002 Jun; 165(11):1526-30. PubMed ID: 12045127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
    Hibma JE; Radtke KK; Dorman SE; Jindani A; Dooley KE; Weiner M; McIlleron HM; Savic RM
    Am J Respir Crit Care Med; 2020 Sep; 202(6):866-877. PubMed ID: 32412342
    [No Abstract]   [Full Text] [Related]  

  • 34. Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.
    Egelund EF; Weiner M; Singh RP; Prihoda TJ; Gelfond JA; Derendorf H; Mac Kenzie WR; Peloquin CA
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4904-10. PubMed ID: 24841270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
    Vernon A; Burman W; Benator D; Khan A; Bozeman L
    Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.
    Dooley KE; Bliven-Sizemore EE; Weiner M; Lu Y; Nuermberger EL; Hubbard WC; Fuchs EJ; Melia MT; Burman WJ; Dorman SE
    Clin Pharmacol Ther; 2012 May; 91(5):881-8. PubMed ID: 22472995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
    Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
    Eur J Pharm Biopharm; 2016 Oct; 107():205-14. PubMed ID: 27422209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.
    Langdon G; Wilkins JJ; Smith PJ; McIlleron H
    Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
    Dorman SE; Savic RM; Goldberg S; Stout JE; Schluger N; Muzanyi G; Johnson JL; Nahid P; Hecker EJ; Heilig CM; Bozeman L; Feng PJ; Moro RN; MacKenzie W; Dooley KE; Nuermberger EL; Vernon A; Weiner M;
    Am J Respir Crit Care Med; 2015 Feb; 191(3):333-43. PubMed ID: 25489785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.